Navigation Links
Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Date:2/13/2008

FRAZER, Pa., Feb. 13 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) issued the following statement in response to a complaint filed today by the U.S. Federal Trade Commission (FTC) in U.S. District Court for the District of Columbia challenging the validity of certain agreements entered into by the company in late 2005 and early 2006 to settle the PROVIGIL(R) (modafinil) [C-IV] patent infringement litigation and seeking to permanently enjoin the Company from maintaining or enforcing these agreements.

Cephalon stands by the strength and validity of our PROVIGIL patents and the legal basis for these settlements. We are disappointed that the FTC has determined to challenge these agreements as we believe they fully comply with both the spirit and letter of the antitrust laws. As importantly, our settlements confer a meaningful benefit to U.S. consumers by providing for the entry of generic modafinil three years early.

Cephalon is prepared to vigorously defend itself in this matter and expects to prevail.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL, FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone fo
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
2. Cephalon General Counsel John E. Osborn to Resign Position
3. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
4. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
5. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Announces Strong Third Quarter Financial Results
9. Cephalon Quarterly Conference Call Invitation
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... 2014 On Friday, December 19, 2014, ... and Continuing Resolution Appropriations Act of 2015, which for ... receive funding through the Congressionally Directed Medical Research Programs ... Hydrocephalus Association (HA), working in conjunction with its allies ...
(Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... , LA JOLLA, Calif., Nov. 16 Fate ... a $30 million Series B financing led by OVP Venture ... a syndicate of corporate investors, including Astellas Venture Management, Genzyme ... co-leaders of the Company,s Series A financing, ARCH Venture Partners, ...
... Institute of Standards and Technology (NIST) have demonstrated ... run any program allowed by quantum mechanicsthe rules ... of information. The processor could be a module ... solve some important,problems that are intractable today. ...
... has received a 4.9 million funding boost from The ... used for invisibility ,cloaking, devices, sensitive security sensors that ... lenses that can be used to image tiny objects ... The new grant has been made to a team ...
Cached Biology Technology:Fate Therapeutics Closes $30 Million Series B Financing 2Fate Therapeutics Closes $30 Million Series B Financing 3Fate Therapeutics Closes $30 Million Series B Financing 4NIST demonstrates 'universal' programmable quantum processor 2NIST demonstrates 'universal' programmable quantum processor 3NIST demonstrates 'universal' programmable quantum processor 4£4.9 million to develop metamaterials for 'invisibility cloaks' and 'perfect lenses' 2£4.9 million to develop metamaterials for 'invisibility cloaks' and 'perfect lenses' 3
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... sectors including technology and tech stocks, releases video from the ... pickpocket and security consultant Apollo Robbins . ... about the Wocket™ biometric smart wallet, a product of NXT-ID, ...
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... http://photos.prnewswire.com/prnh/20130307/600769 ... introduced the fingerprint reading feature with the iPhone 5S. ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... molecular fingerprints of what your cells are up to and ... cancer. You,ve likely heard about metabolites; your physician probably ... at your annual physical. Scientists suspect we have about 3,000 ... different compounds in our bodies. Dr. Sreekumar, ...
... 2009 A review by researchers at Northwestern University ... of the utility of probiotics in the treatment of ... 35624 was the only probiotic strain out of ... improve symptoms of IBS, including abdominal pain, bloating and ...
... at your desk and suddenly your heart is beating ... on fumes. It is a shocking, uncomfortable and frightening ... cause of sudden cardiac death or SCD, a condition ... States. Scientists are now closer to understanding what causes ...
Cached Biology News:Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment 2Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment 3Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment 4Review of probiotic trial research finds only Bifantis able to claim efficacy for IBS symptoms 2Ten genes identified in connection with sudden cardiac death 2
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
... Savant's latest SpeedVac Concentrator, the SPD series ... a new modern twist., The SPD121P SpeedVac ... gauge for optimizing runs; preventing samples from ... stopped at the end-users preset level., Standard ...
... to create the ideal environment for nucleic acid ... , Variable speed control (10 to 15 ... be for washing or hybridizing , A ... the chamber, ,is situated above a touch sensitive ...
... latest edition to the famous SpeedVac concentrator ... large diameter exhaust port for improved drying ... precise setting and control of all important ... quantities and samples , STANDARD TEFLON ...
Biology Products: